CSL300

BIOLOGICAL2 trials

Sponsors

CSL Behring

Conditions

End Stage Kidney DiseaseEnd Stage Kidney Disease (ESKD)

Phase 1

A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

RecruitingNCT07619820

CSL BehringEnd Stage Kidney Disease (ESKD)

Start: 2026-06-17End: 2027-11-30Target: 24Updated: 2026-07-07

Phase 2

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

RecruitingNCT05485961

CSL BehringEnd Stage Kidney Disease

Start: 2022-10-21End: 2029-05-22Target: 3110Updated: 2026-08-11

Related Papers

IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial

Nature Medicine2024-05-2557 citations